

**REMARKS**

Claims 1-5, 14-16, 18, and 20-35 are pending and have been allowed pursuant to the Notice of Allowance mailed December 19, 2005. The issue fee has not yet been paid.

In the present amendment, the Abstract and claims 1-5, 14-16, 18, 20-26 and 30-35 have been amended to correct a minor typographical error in the recited formal chemical name for tenatoprazole. Specifically, the recited compound name has been corrected to read (-)-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]imidazol[4,5-b]pyridine, rather than (-)-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfonyl]imidazol[4,5-b]pyridine. Applicants note that the correct formal chemical name for tenatoprazole can be found throughout the specification, including in the original claims. Therefore, no new matter has been added. Claim 29 has also been amended to recite the formal chemical name for tenatoprazole, namely, (-)-5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]imidazol[4,5-b]pyridine.


Entry of the present amendment is requested as the amendment merely addresses formal matters. By the present amendment, no new issues are presented for the Examiner's consideration. Accordingly, entry of the amendment as being directed to formal matters without changing the scope of the claims is respectfully requested.

In the event that there are any questions relating to this application, it would be appreciated if the Examiner would telephone the undersigned attorney concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,  
BUCHANAN INGERSOLL PC

Date: January 6, 2006

By:

  
Melissa M. Hayworth  
Registration No. 45,774

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620